News & Updates

‘1-2-3-4-day rule’: Initiating DOACs according to stroke severity may be the way to go

23 May 2022 by

Following nonvalvular atrial fibrillation (NVAF)-associated stroke events, a graded increase in delay in direct oral anticoagulants (DOACs) initiation of between 1 and 4 days, depending on the severity of the index event, appears to be effective for recurrent stroke prevention and does not compromise safety both in Asians and Europeans, according to a recent study.

‘1-2-3-4-day rule’: Initiating DOACs according to stroke severity may be the way to go

23 May 2022

Steroid plus anti-TNF-α proven effective in SJS/TEN

23 May 2022

The addition of antitumour necrosis factor-alpha (anti-TNF-α) to steroid treatment may help improve outcomes for patients with Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN), suggest the results of a recent study.

Steroid plus anti-TNF-α proven effective in SJS/TEN

23 May 2022

Upadacitinib provides robust, long-term control of moderate-to-severe AD

23 May 2022 by

Follow-up data from two replicate ongoing phase III trials – Measure Up 1 and Measure Up 2 – demonstrated favourable longer-term benefit-risk profile of upadacitinib in adolescents and adults with moderate-to-severe atopic dermatitis (AD).

Upadacitinib provides robust, long-term control of moderate-to-severe AD

23 May 2022

$Early initiation of anti-osteoporosis medication reduces fracture events$

Early initiation of anti-osteoporosis medication reduces fracture events

22 May 2022

For patients on glucocorticoid therapy, a delay in anti-osteoporosis treatment initiation may lead to increased fracture events, while early treatment helps to prevent them, a study has found.

Early initiation of anti-osteoporosis medication reduces fracture events

22 May 2022

Which canagliflozin dose is best for T2DM patients with hypertension?

22 May 2022

A recent meta-analysis offers new proof of different canagliflozin doses for hypertension management in patients with type 2 diabetes mellitus (T2DM) complicated by hypertension. However, low-density lipoprotein cholesterol (LDL-C) and the risk of urinary tract infection must be observed.

Which canagliflozin dose is best for T2DM patients with hypertension?

22 May 2022

Early evolocumab helps reduce LDL-C levels, prevent recurrent ischaemic cardiovascular events

21 May 2022

In acute coronary syndrome (ACS) patients who have undergone percutaneous coronary intervention (PCI), early treatment with evolocumab as an addition to statin can lower low-density lipoprotein cholesterol (LDL-C) levels as well as reduce the incidence of recurrent ischemic cardiovascular events, while having satisfactory tolerability and safety, according to a study.

Early evolocumab helps reduce LDL-C levels, prevent recurrent ischaemic cardiovascular events

21 May 2022

Fezolinetant reduces hot flashes in menopausal women

21 May 2022 by

Treatment with fezolinetant significantly reduced the frequency and severity of vasomotor symptoms (VMS), particularly hot flashes, in women during their menopausal phase, according to the SKYLIGHT 1* trial presented at ACOG 2022.